No Data
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $90
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $78
Celldex Therapeutics (NASDAQ:CLDX) Pulls Back 6.1% This Week, but Still Delivers Shareholders Fantastic 57% CAGR Over 5 Years
Express News | Celldex: Barzolvolimab has reached the endpoint in chronic urticaria research.
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints With High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
No Data
No Data